Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
P A Francis, O Pagani, G F Fleming et al.
✦ AI-curated · Sources linked
In 30 seconds
The SOFT and TEXT phase III trials evaluated the long-term outcomes of ovarian function suppression (OFS) combined with tamoxifen or exemestane in premenopausal women with hormone receptor-positive early breast cancer. The final 15-year results showed that exemestane plus OFS significantly reduced distant recurrence compared to tamoxifen plus OFS (HR 0.75, 95% CI 0.63-0.90) in HER2-negative tumors, highlighting the importance of treatment choice in high-risk populations.
Key findings
- 15-year breast cancer-free interval was 78.6% for exemestane+OFS versus 75.7% for tamoxifen+OFS.
- In HER2-negative tumors, exemestane+OFS reduced distant recurrence by 25% compared to tamoxifen+OFS.
- 15-year overall survival rates were 81.0% for exemestane+OFS and 76.8% for tamoxifen alone in the no-chemotherapy cohort.
Why it matters
These findings underscore the need for tailored treatment strategies in premenopausal women with hormone receptor-positive breast cancer, particularly for those with high-risk features, to optimize long-term outcomes and reduce recurrence rates.